Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

23.12.2024

1 Am J Obstet Gynecol
2 BMC Cancer
2 Br J Cancer
1 Cancer Lett
1 Clin Cancer Res
9 Gynecol Oncol
1 Int J Cancer
1 Int J Gynaecol Obstet
4 Int J Gynecol Pathol
1 J Clin Oncol
1 J Natl Cancer Inst
1 Obstet Gynecol
1 Oncogene
1 PLoS Genet
6 PLoS One



    Am J Obstet Gynecol

  1. WU P, Zhou J, Zhang Y
    Incorporation of BRCA1 testing into prenatal carrier screening for hereditary breast and ovarian cancer prevention should take carrier rates into account.
    Am J Obstet Gynecol. 2024 Dec 11:S0002-9378(24)01181.
    >> Share


    BMC Cancer

  2. HUO C, Wu B, Ye D, Xu M, et al
    New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer.
    BMC Cancer. 2024;24:1536.
    >> Share

  3. SCHMIDT M, Vernooij R, van Nuland M, Smeijsters E, et al
    Impaired liver function: effect on paclitaxel toxicity, dose modifications and overall survival.
    BMC Cancer. 2024;24:1553.
    >> Share


    Br J Cancer

  4. MERRITT MA, Abe SK, Islam MR, Rahman MS, et al
    Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium.
    Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02924.
    >> Share

  5. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    >> Share


    Cancer Lett

  6. LOMELI N, Pearre DC, Lepe J, Argueta DA, et al
    N-acetylcysteine prevents cisplatin-induced cognitive impairments in an ovarian cancer rat model.
    Cancer Lett. 2024 Dec 18:217405. doi: 10.1016/j.canlet.2024.217405.
    >> Share


    Clin Cancer Res

  7. SCHULTZ KAP, Nelson AT, Mallinger PHR, Harris AK, et al
    DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
    Clin Cancer Res. 2024;30:5681-5692.
    >> Share


    Gynecol Oncol

  8. JANG EB, Lee AJ, So KA, Lee SJ, et al
    Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
    Gynecol Oncol. 2024;191:19-24.
    >> Share

  9. WAN S, Gao Y, Wu S, Wang H, et al
    Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
    Gynecol Oncol. 2024;191:56-66.
    >> Share

  10. RUSHTON T, Krause HB, Samec T, Elliott A, et al
    Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:80-85.
    >> Share

  11. YONEMORI K, Boni V, Min KG, Meniawy TM, et al
    Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
    Gynecol Oncol. 2024;191:172-181.
    >> Share

  12. HICKEY M, Trainer AH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
    Gynecol Oncol. 2024;191:201-211.
    >> Share

  13. GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
    Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
    Gynecol Oncol. 2024;191:233-239.
    >> Share

  14. GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
    Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
    Gynecol Oncol. 2024;192:120-127.
    >> Share

  15. AZAIS H, Brochard C, Taly V, Benoit L, et al
    Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
    Gynecol Oncol. 2024;192:145-154.
    >> Share

  16. KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
    Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
    Gynecol Oncol. 2024;192:155-162.
    >> Share


    Int J Cancer

  17. VERROU E, Koutoukoglou P, Kontana E, Gogolopoulos S, et al
    Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
    Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35299.
    >> Share


    Int J Gynaecol Obstet

  18. ALSHWAYYAT S, Abo-Elnour DE, Dabash TY, Alshwayyat TA, et al
    Personalized approach to malignant struma ovarii: Insights from a web-based machine learning tool.
    Int J Gynaecol Obstet. 2025;168:343-352.
    >> Share


    Int J Gynecol Pathol

  19. WANG L, Vasudevaraja V, Tran I, Sukhadia P, et al
    Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors.
    Int J Gynecol Pathol. 2025;44:88-93.
    >> Share

  20. DE BOECK A, Nohr E, El-Hallani S, Ghatage P, et al
    POLE-mutated Endometrial "Carcinosarcoma".
    Int J Gynecol Pathol. 2025;44:72-78.
    >> Share

  21. DEL MUNDO MM, Aguilar M, Chen H, Niu S, et al
    beta-catenin, PAX2, and PTEN Aberrancy Across the Spectrum of Endometrioid Ovarian Lesions.
    Int J Gynecol Pathol. 2025;44:79-87.
    >> Share

  22. CHRISTENSEN D, Ghafoor M, Goldberg A, De Cotiis DA, et al
    Tumor Budding, Poorly Differentiated Clusters, and Stroma Percentage in Uterine Endometrioid Carcinomas Are Morphologic Findings Associated With Adverse Clinical Outcomes.
    Int J Gynecol Pathol. 2025;44:49-55.
    >> Share


    J Clin Oncol

  23. SCAMBIA G, Villalobos Valencia R, Colombo N, Cibula D, et al
    Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
    J Clin Oncol. 2024 Dec 12:JCO2400933. doi: 10.1200/JCO.24.00933.
    >> Share


    J Natl Cancer Inst

  24. ELZE L, van der Post RS, Vos JR, Mensenkamp AR, et al
    Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.
    J Natl Cancer Inst. 2024;116:1904-1913.
    >> Share


    Obstet Gynecol

  25. PENNINGTON KP, Pugh SL, Huh W, Walker JL, et al
    Optimization of Timing for Risk-Reducing Salpingectomy and Oophorectomy.
    Obstet Gynecol. 2025;145:21-30.
    >> Share


    Oncogene

  26. ZHAI X, Shen N, Guo T, Wang J, et al
    SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression.
    Oncogene. 2024 Dec 7. doi: 10.1038/s41388-024-03249.
    >> Share


    PLoS Genet

  27. RIVERA IS, French JD, Bitar M, Sivakumaran H, et al
    GWAS and 3D chromatin mapping identifies multicancer risk genes associated with hormone-dependent cancers.
    PLoS Genet. 2024;20:e1011490.
    >> Share


    PLoS One

  28. WEINSTEIN SJ, Parisi D, Mondul AM, Layne TM, et al
    Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    PLoS One. 2024;19:e0315252.
    >> Share

  29. RUSSO D, Spina A, Portella L, Bello AM, et al
    The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.
    PLoS One. 2024;19:e0314735.
    >> Share

  30. PERAMPALAM P, McDonald JI, Dick FA
    GO-CRISPR: A highly controlled workflow to discover gene essentiality in loss-of-function screens.
    PLoS One. 2024;19:e0315923.
    >> Share

  31. SENGUPTA D, Ali SN, Bhattacharya A, Mustafi J, et al
    Correction: A deep hybrid learning pipeline for accurate diagnosis of ovarian cancer based on nuclear morphology.
    PLoS One. 2024;19:e0316114.
    >> Share

  32. WANG H, Han X, Niu S, Cheng H, et al
    DFASGCNS: A prognostic model for ovarian cancer prediction based on dual fusion channels and stacked graph convolution.
    PLoS One. 2024;19:e0315924.
    >> Share

  33. LOPACINSKA-JORGENSEN J, Oliveira DVNP, Novotny GW, Hogdall CK, et al
    Correction: Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer.
    PLoS One. 2024;19:e0315859.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016